Amprius Technologies Inc
For the period ended Jun 30, 2024. Filed Aug 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 9, 2024
AMPX$9.17-3.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six months ended June 30, | ||
|---|---|---|
| (In thousands) | 2024 | 2023 |
| Cash flows from operating activities: | ||
| Net loss | $(22,403) | $(18,550) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 3,188 | 1,650 |
| Depreciation and amortization | 2,053 | 856 |
| Amortization of deferred costs | — | 402 |
| Non-cash operating lease expense | 2,571 | 506 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (473) | (444) |
| Inventories | (797) | (3) |
| Deferred costs | (380) | (1,304) |
| Prepaid expenses and other current assets | (185) | 915 |
| Other assets | (12) | (9) |
| Accounts payable | 2,061 | (305) |
| Accrued and other current liabilities | (2,518) | 3,903 |
| Deferred revenue | (283) | 761 |
| Operating lease liabilities | (560) | (453) |
| Net cash used in operating activities | (17,738) | (12,075) |
| Cash flows from investing activities: | ||
| Purchase of property, plant and equipment | (5,501) | (2,868) |
| Net cash used in investing activities | (5,501) | (2,868) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock upon exercise of stock warrants | 14,384 | 1 |
| Proceeds from issuance of common stock in connection with the At Market Issuance Sales Agreement | 10,861 | — |
| Proceeds from issuance of common stock in connection with the Stock Purchase Agreement | — | 10,507 |
| Payment of equity financing costs | (216) | (254) |
| Proceeds from exercise of stock options | 96 | 3 |
| Net cash provided by financing activities | 25,125 | 10,257 |
| Net increase (decrease) in cash, cash equivalents and restricted cash equivalents | 1,886 | (4,686) |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | 45,817 | 69,752 |
| Cash, cash equivalents and restricted cash equivalents, end of period | $47,703 | $65,066 |
| Reconciliation of cash, cash equivalents and restricted cash equivalents shown on the condensed consolidated balance sheets: | ||
| Cash and cash equivalents | $46,447 | $65,010 |
| Restricted cash equivalents included in other assets | 1,256 | 56 |
| Total cash, cash equivalents and restricted cash equivalents | $47,703 | $65,066 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.